An internal Source-Omega report suggests at 3 months, high triglyceride reductions with DHA are temporally correlated with omega-3 essentiality, or saturation levels of omega-3s in red blood cell (RBC) membranes, also called the omega-3 index.

Chapel Hill, NC, November 29, 2010 — An interview this week with Baldur Hjaltason, chairman of leading marine-sourced omega-3 group the Global Organization for EPA and DHA Omega-3 (GOED), and strategic business development manager at EPAX, and Adam Ismail, GOED executive director. On November 23, 2010, when asked by Nutraingredients reporter Shane Starling about the 2.0 g DHA claim for triglycerides management, Baldur Hjaltason said, “The omega-3 industry has been driven by solid science. That is the reason we are seeing so many approved claims, because we have such a great amount of scientific data to support those claims.”

The long-chain omega-3 fatty acid docosahexaenoic acid (DHA; 22:6 n-3) comprises over 80 percent of the omega-3 composition in the human body. This fact has not escaped non-fish-based advocates of algae oil DHA treatments for high triglycerides. The literature shows over 16 studies of algae oil DHA supplements providing significant improvements in hypertrygliceridemia (HTG), commonly known as high triglyceride levels above 200 mg/dl triglycerides in plasma in a fasting state.

Since high triglycerides are commonly found in type 2 diabetes subjects, Source-Omega ( http://www.source-omega.com ) recently conducted a study of the mechanisms and evidence for how DHA might protect against diabetic etiologies affected by high triglycerides. “We observed that DHA-rich microalgae oil is more effective than fish oil mixtures low in DHA at lowering high postprandial triglyceride levels,” said Scott Doughman, Ph.D., Chief Scientist at Source-Omega.

Source-Omega has also been looking at the need in Asian Indian urban populations particularly at risk for HTG and diabetes onset due to factors such as urbanization, dietary changes and genetic factors inherent to the traditionally non-fish-eating population.

Source-Omega’s Report Findings:

1) Clinical studies in the United States and elsewhere show DHA from microalgae oil targets HTG.

2) At 3 months, the HTG reductions with DHA are temporally correlated with omega-3 essentiality, or saturation levels of omega-3s in red blood cell (RBC) membranes, also called the omega-3 index.

3) DHA reduces triglyceride levels over 25 percent when taken at levels greater than 1000 mg daily for 3 months, doubling total omega-3 levels.

4) 1200 mg DHA per day gives about 1000 mg bioavailable DHA.

5) DHA is the major omega-3 present in neuroendocrine beta-cell membranes and in immunological cells.

6) While microalgae oil DHA studies have not been performed using insulin producing cells, fish oil studies clearly show DHA is the only accretive omega-3 in pancreatic beta-cell membranes.

7) While DHA does not affect glucose homeostasis in diabetic subjects, increases in DHA levels over time correlated with improvements in insulin secretion and insulin function, suggesting beta-cell dependent and independent mechanisms.

8) The utility of 1200 mg DHA as an optimized dosage for the reduction of moderately high HTG and a low plasma omega-3 index for optimizing health status was supported by several independent studies as a near-maximal metabolic dose for greatest results per dose.

About Source-Omega, LLC:
Located in Chapel Hill North Carolina, founded in 2007, Source-Omega developed the Pure One™ Formula out of the published academic work and innovations of Scott Doughman, Ph.D., Lipid Biochemist and a former National Institutes of Health funded omega-3 researcher, previously also an American Heart Association fellow with over 12 years of lipid research experience. Since 2007, the company has rapidly grown with a focus on high triglycerides and their Omega-3 DHA Therapy™ for results oriented omega-3 dosages. The product stability, ecological sustainability, vegan and Kosher registrations and research behind Pure One™, each lend qualifications that provide value added advantages. The Pure One™ Brand and Formula are available for licensing from Source-Omega.

Press & Media Contact:
Scott D. Doughman, PhD
Source-Omega, LLC
52 Norwood Rd
Chapel Hill, NC 27516 USA
919-360-5275
info@source-omega.com
http://www.source-omega.com

Source-Omega licenses Solal Technologies of Johannesburg, South Africa, to offer novel Vegetarian Omega-3 (SM) product with DHA and EPA from sustainable algae oil source.

Chapel Hill, NC, November 24, 2010 — Source-Omega, LLC ( http://www.source-omega.com ) is now offering private labeling of its vegetarian algae oil in international markets.

The company has licensed Solal Technologies of Johannesburg, South Africa, to offer Vegetarian Omega-3 (SM).

“Solal is an ideal business partner for Source-Omega,” said Dr. Scott Doughman, president and founder of Source-Omega. “Both companies have the same goal, offering a product that fills an important need not met with modern diets and lifestyle.”

The oil has been licensed for sale in the South African pharmaceutical market under a “medical food” label licensed to Solal under the Pure One™ brand.

“Medical food” is a relatively new category established in the 1988 amendments to the Orphan Drug Act. The U.S. Food and Drug Administration requires that “medical foods” contain only ingredients classified as Generally Regarded as Safe (GRAS). Algae oil omega-3, which is entirely plant-based, meets this standard, however the Pure One™ label in the U.S. and South Africa are designated Dietary Supplements and are not a drug.

Solal will offer Vegetarian Omega-3 in pharmacies, behind the counter, as recommended by physicians for management of a low omega-3 index and high triglyceride levels. It will also be offered as an anti-aging non-prescription supplement. Vegetarian Omega-3 will be available directly to patients, through retail pharmacies, physicians and health stores based in South Africa.

“We are pleased to have this relationship with Source-Omega to offer a product that is so important to maintaining health,” said Colin Levin, a vegetarian and a director of Solal. “This will be a win-win-win, for Solal, Source-Omega, and, most importantly, for our patients and customers.”

Source-Omega is also working on expanding its markets through other private labeling arrangements outside the United States.

The basis of the oil is Source-Omega’s patent-pending formula of DHA and EPA for cardiovascular, metabolic and cognitive health management, offered in supplements and medical food. Pure One™ offers optimized omega-3 dosages and clinically proven triglyceride lowering benefits with documented results.

Certain omega-3 dosages have been proven effective for management of plasma lipids. As a medical food, it can fulfill the omega-3 requirements associated with DHA and EPA deficiencies in vegetarians, people who cannot eat fish, and those with special dietary needs not met by omega-3 seed sources such as flax oil. Vegetarian Omega-3(SM) is offered in a soft carrageenan capsule.

About Solal Technologies (Pty) Ltd: Located in Johannesburg, Solal Technologies works and supplies online to physicians, pharmacies and other outlets based in South Africa. Other divisions of Solal include The Compounding Pharmacy of South Africa, an Integrative Medical Center and a Health Intelligence magazine covering the science of health. For more information please visit http://www.solaltech.com

About Source-Omega, LLC:
Located in Chapel Hill North Carolina, founded in 2007, Source-Omega developed the Pure One™ Formula out of the published academic work and innovations of Scott Doughman, Ph.D., Lipid Biochemist and a former National Institutes of Health funded omega-3 researcher, previously also an American Heart Association fellow with over 12 years of lipid research experience. Since 2007, the company has rapidly grown with a focus on high triglycerides and their Omega-3 DHA Therapy™ for results oriented omega-3 dosages. The product stability, ecological sustainability, vegan and Kosher registrations and research behind Pure One™, each lend qualifications that provide value added advantages. The Pure One™ Brand and Formula are available for licensing from Source-Omega, LLC under their field of use and US patent application number 12/727,006 filed with the US Trademark and Patent Office, March 18th, 2010.

For more information please visit http://www.source-omega.com.

Press & Media Contact:
Scott D. Doughman, PhD
Source-Omega, LLC
52 Norwood Rd
Chapel Hill, NC 27516 USA
919-360-5275
info@source-omega.com
http://www.source-omega.com